Sef de Lucrari Dr. Nicolae Mircea PANDURU

Slides:



Advertisements
Similar presentations
Prof.Briciu Daniela Sc.cu cls. I-VIII Luna de Sus
Advertisements

Practical implementation of the ADVANCE results in real life Davide Carvalho Centro Hospitalar S. João, University of Porto Medical School, Portugal 12.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
Pneumonia nosocomiala = pneumonia de spital, dobindita ca urmare a spitalizarii, “hospital- acquired pneumonia”
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Încărcătura de muncă în cabinetul medicului de familie, referitor la managementul pacienţilor hipertensivi. Dr. Andrea Abăităncei Dr. Claudia Ulieru.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Blood glucose: is lower better for diabetic patients?
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Diabetul zaharat tip 2 şi riscul de boală cardiovasculară
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Glycemic Control: When the Lower is Not the “Better”?
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
A Diabetes Outcome Progression Trial
Individualization Strategies for Older Patients with Diabetes Elbert S. Huang, MD MPH FACP University of Chicago.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
Therapy of Type 2 Diabetes Mellitus: UPDATE
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Therapy of Type 2 Diabetes Mellitus: UPDATE Glycemic Goals in the Care of Patients with Type 2 Diabetes ADA and AACE Guidelines: Room For Improvement.
Achieving Glycemic Control in the Hospital Setting (Part 2 of 4)
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
An initiative of South Asian Federation of Endocrine Societies (SAFES)
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.
Glycemia Treatment Strategies Used In ACCORD
Dr John Cox Diabetes in Primary Care Conference Cork
Achieving Optimal Glycaemic Control: Can Insulin Deliver?
Management of Diabetes in the Older Person
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
Volume 352, Issue 9131, Pages (September 1998)
Insulin Delivery Systems Atlanta Diabetes Associates
Neal B, et al. Diabetes Care 2015;38:403–411
Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.
US Medical Professionals’ Knowledge of the Diabetes Control and Complications Trial Austin Bach, DO, MPH, Mohamad ElChurafa, BS, Daniel Solano, DO, Marcos.
Copyright © 2017 American Academy of Pediatrics.
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
Therapy of Type 2 Diabetes Mellitus: UPDATE
Oracle Academy Lead Adjunct
Funcţii Excel definite de utilizator (FDU) în VBA
Posibilităţi de analiză în timp real a parametrilor de calitate a apei cu ajutorul sistemului informatic de management SIVECO Business Analyzer September.
Management of Diabetes in the Older Person
Macrovascular Complications Microvascular Complications
Infectii respiratorii asociate ventilatiei noninvazive
PICIORUL DIABETIC Principalele modificări determinate de: neuropatie
Controlul glicemic la pacientul cu DZ2
Value of construct 1. Fits with Harry Keen’s construct
Necesitatile nutritionale ale pacientilor cu cerinte speciale
Cardiovascular (CV) Safety and Severe Hypoglycemia Benefit of Insulin Degludec vs Insulin Glargine U100 in Older Patients (≥65 years) with Type 2 Diabetes.
on behalf of the LEADER Trial Steering Committee and Investigators
Diabetul zaharat – definiţie, clasificare, epidemiologie
Funcții C/C++ continuare
↑- likely due to hypoglycemia and weight gain
Complicaţiile microvasculare ale DZ 2.
A great way to create a channel of communication
Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!
ACNEEA - O BOALA TRATABILĂ
UNIVERSITATEA DE MEDICINA SI FARMACIE “Gr. T
Glycemic control for macrovascular disease in type II diabetes: Evidence and insights from recent trials  Sanjay Rajagopalan  Journal of Indian College.
Key Insulin Side Effects*
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
New frontiers in Diabetes management
Strategies for Optimizing Glycemic Control and Cardiovascular Prognosis in Patients With Type 2 Diabetes Mellitus  James H. O'Keefe, MD, Mohammad Abuannadi,
Hyperglycemic Targets & Hypoglycemia
Presentation transcript:

Sef de Lucrari Dr. Nicolae Mircea PANDURU UNIVERSITATEA DE MEDICINĂ ŞI FARMACIE „CAROL DAVILA” DIN BUCUREŞTI Departamentul Clinic II Disciplina Diabet, Nutritie si Boli Metabolice HIPOGLICEMIA Sef de Lucrari Dr. Nicolae Mircea PANDURU

CUPRINS Definitie Clasificare Mecanisme compensatorii Efecte fiziopatologice Cauze Hipoglicemie la pacientul cu diabet zaharat Prevalenta Factori de risc Tratament Complicatii hipoglicemiilor severe si prelungite Educatia anturajului

Definitie - Triada Whiple HIPOGLICEMIA Definitie - Triada Whiple simptome şi semne sugestive de hipoglicemie Initial – semne si simptome autonome Apoi – semne si simptome neuroglicopenice Final – semne si simptome neurologice hipoglicemie evidenţiată pe baza examenelor de laborator, dispariţia simptomelor prin aplicarea metodelor terapeutice de creştere la normal a glicemiei

Simptome şi semne sugestive HIPOGLICEMIA Simptome şi semne sugestive Autonome Neuroglicopenice Neurologice Transpiratii Slabiciune Instabilitate Tremuraturi Somnolenta Coordonare dificila Palpitatii, tahicardie Tulburari de concentrare Vedere dubla Paloare Ameteala Incetosarea vederii Anxietate Confuzie Tulburari de vorbire Nervozitate Senzatie de “cap greu” Comportament bizar Coma hipoglicemica: - Debut brusc (în plina activitate); - Debut precedat de semne premonitorii; - Debut în somn (respiratie zgomotoasa, transpiratii profuze, convulsii, cosmar).

Alte manifestari - Efectul hipoglicemiei asupra intervalului QT HIPOGLICEMIA Alte manifestari - Efectul hipoglicemiei asupra intervalului QT 90 mg/dl 45 mg/dl B A QTc= 610 ms HR= 61 bpm QTc= 456 ms HR= 66 bpm Prelungire QT Aritmii severe, IMA - mai frecvente la pacientii cu boala cardiaca ischemica Tahicardie, cresterea TA International Diabetes Monitor 2009; 21(6): 234-241.

Hipoglicemie evidenţiată pe baza examenelor de laborator - definitie HIPOGLICEMIA Hipoglicemie evidenţiată pe baza examenelor de laborator - definitie • La persoanele sanatoase simptomele apar la glicemie de 60 mg/dl si alterarea functiilor creierului la ˜ 50 mg/dl. • La pacientii cu diabet zaharat: < 72 mg/dl (4 mmol/l) ADA 2005 American Diabetes Association (ADA) workgroup on Hypoglycaemia. Defining and reporting hypoglycaemia in diabetes. Diabetes Care 2005;28:1245–1249. < 54 mg/dl (3 mmol/l) European Agency for Evaluation of Medicinal Products (EMEA) Note for guidance on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2006. < 70 mg/dl (3.9 mmol/l) European Agency for Evaluation of Medicinal Products (EMEA) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012 utilitate clinica: < 63 mg/dl (3,5 mmol/l) – glicemia de la care pacientii trebuie sa initieze actiuni corectoare

HIPOGLICEMIA Clasificare Usoara Simptomele autonome sunt prezente Individul este capabil sa se auto-trateze Moderata Simptomele autonome si neuroglicopenice sunt prezente Severa Necesita asistenta din partea altei persoane Pierderea de cunostinta poate aparea Glicemia tipica este < 50 mg/dl (2.8 mmol/L)

Mecanisme compensatorii HIPOGLICEMIA Mecanisme compensatorii Scaderea secretiei de insulina – la glicemie ≈ 80 mg/dl – creste productia hepatica si renala de glucoza si scade utilizarea periferica de glucoza • Glucagon – stimuleaza glicogenoliza si neoglucogeneza hepatica • Stimularea simpatica – inhiba secretia de insulina – utilizarea periferica a glucozei – stimuleaza lipoliza si proteoliza – glicogenoliza în muschi Cortizol, hormon de crestere – în hipoglicemii prelungite, mai severe – nu contribuie substantial la contrareglarea acuta

Mecanisme compensatorii HIPOGLICEMIA Mecanisme compensatorii Service FJ: N Engl J Med 1995; 332: 1144-1152

Efecte fiziopatologice HIPOGLICEMIA Efecte fiziopatologice • glucoza - singura sursa imediata de energie pentru celula nervoasa • corpii cetonici - a doua sursa energetica pentru celula nervoasa; operanta în timp • leziuni cerebrale în hipoglicemia severa – asemanatoare cu cele din hipoxie – initial: la nivelul neuronilor - microvacuolizare – ulterior modificari ischemice celulare • hipoglicemii severe prelungite: apar leziuni ireversibile corticale — subcorticale —bulbare.

HIPOGLICEMIA IN DIABETUL ZAHARAT Prevalenta la pacientii cu diabet zaharat tip 1 Severe hypoglycemia Cognitive dysfunction, loss of consciousness, seizure, death Pacienti cu control glicemic strâns: - 2 episoade hipoglicemice / saptamâna minim o hipoglicemie severa /an. • Multe episoade de hipoglicemie asimptomatica (<60mg/dl). • DCCT cel putin un episod de hipoglicemie severa / an - 65% cazuri.

HIPOGLICEMIA IN DIABETUL ZAHARAT Prevalenta la pacientii cu diabet zaharat tip 2 10 20 30 40 Rata anuala (%) 4 5 6 7 8 9 11 Cea mai recenta HbA1C (%) • Aproximativ 10% din pacientii insulinotratati prezinta o hipoglicemie severa/an. • UKDPS: cel putin un episod de hipoglicemie severa / an la: - 3,3% din pacientii tratati cu sulfoniluree - 11,2% din pacientii tratati cu insulina. • Mai frecventa la tineri sau la persoanele vârstnice. Wright et al. J Diabetes Complications. 2006;20:395-401.

HIPOGLICEMIA IN DIABETUL ZAHARAT Riscul unei hipoglicemii severe creste cu durata tratamentului cu insulina 8 7 6 5 Durata medie a tratamentului cu insulina (ani) 4 3 2 1 DZ tip 2 DZ tip 1 Fara hipoglicemii severe Hipoglicemii severe Hepburn et al. Diabetic Med 1993; 10(3): 231-7.

HIPOGLICEMIA IN DIABETUL ZAHARAT Hipoglicemiile si tratamentul cu ADO sau insulina Orice Hipoglicemie Hipoglicemie severa 40 3.0 36.5 2.5 2.3 30 2.0 Media (%) Media (%) 20 17.7 1.5 11 1.0 10 0.6 0.5 0.4 1.2 0.1 0.0 Dieta Chlorpropamid Glibenclamid Insulina UKPDS 33. Lancet 1998;352:837-853.

HIPOGLICEMIA IN DIABETUL ZAHARAT Hipoglicemiile si tratamentul cu secretagoge sau insulinosensibilizante Orice hipoglicemie Hipoglicemie severa Procentul de pacienti cu hipoglicemie Gliburid Metformin Rosiglitazona Gliburid Metformin Rosiglitazona ADOPT Study N Engl J Med 2006;355:2427-2463.

Hipoglicemiile si rata de filtrare glomerulara HIPOGLICEMIA IN DIABETUL ZAHARAT Hipoglicemiile si rata de filtrare glomerulara Scaderea ratei filtrarii glomerulare si diabetul cresc riscul de hipoglicemie Riscul de hipoglicemie severa (incidence rate ratio) Middleton demonstrated that diabetes patients are much more likely to experience hypoglycaemic side effects with their medication if they also had chronic kidney disease. In fact, of those experiencing severe hypoglycaemic events (including loss of consciousness) with sulphonylurea medications, around 74% had reduced renal function. Reference Middleton RJ, et al. Nephrol Dial Transplant. 2006;21(1):88–92. BRD cu RGF scazut Diabet cu RFG normal Scaderea RFG de alta cauza Fara diabet iar RFG normal Aproximativ 75% din cazurile de hipoglicemie severa (cu pierderea de constienta), secundare tratamentului cu sulfoniluree, apar la pacientii cu afectare renala CJASN 2009;4:1121–27; Nephrol Dial Transplant 2011;26:1888–94 16

HIPOGLICEMIA IN DIABETUL ZAHARAT Hipoglicemiile si tratamentul intensiv ACCORD2 ADVANCE3 Tratament intensiv Tratament conventional Pacienti cu cel putin un episod hipoglicemic sever (%) 5 10 15 20 25 VADT1 2.7% 1.5% 16.2% 5.1% 21.2% 9.9% p<0.001 HR=1.86 (95% CI 1.40–2.40) VADT: severe change in consciousness including loss of consciousness ACCORD: requiring assistance of another person and plasma glucose < 2.8 mmol/l (50 mg/dl) or symptoms that promptly resolved with oral carbohydrate, intravenous glucose, or glucagon. ADVANCE: requiring assistance of another person and plasma glucose <2.8 mmol/l Clinical trials repeatedly demonstrate that intensive treatment, used to achieve very tight Glycemic control, can increase the risk of patients experiencing hypoglycemic episodes. In the VADT, ACCORD and ADVANCE studies, intensive pharmacological treatment resulting in a lower HbA1c at study end, resulted in a greater proportion of patients experiencing at least one episode of severe hypoglycemia. The data are shown here for these three studies. Intensive treatment in the VADT trial led to HbA1C below 7% (compared with 8.4% HbA1c in the standard treatment group). In the intensive treatment group, the number of patients experiencing at least one severe hypoglycemic event was more than doubled compared to the standard treatment group. In the ACCORD trial, intensive treatment resulted in a mean HbA1C of 6.4% at study end, compared to 7.5% in the standard treatment group. The number of patients experiencing severe hypoglycemic events was more than three times higher in the intensive treatment group compared with the std group. A similar trend was observed in the ADVANCE study, where HbA1C was lowered to 6.5% in the intensive treatment group, accompanied by a higher rate of hypoglycemic events. 1. Duckworth W, et al. N Engl J Med.2009;360:129–139; 2. Bonds DE et al, BMJ. 2010;340:b4909. 3. ADVANCE Study Group. N Engl J Med. 2008;358(24):2560-72. Hipoglicemia a fost asociata cu cresterea numarului de evenimente cardiovasculare, indiferent de modul de tratament (intensiv sau conventional) in studiul VADT1 % HbA1c at study end 6.9 8.4 6.4 7.5 6.5 7.3 % change from baseline -2.5 -1.0 -1.7 -0.6 -1.0 -0.2 Duckworth W, et al. N Engl J Med 2009;360:129-39; Bonds DE, et al, BMJ 2010;340:b4909; ADVANCE Study Group. N Engl J Med 2008;358(24):2560-72 17 17

Hipoglicemiile asimptomatice HIPOGLICEMIA IN DIABETUL ZAHARAT Hipoglicemiile asimptomatice 100 75 62.5 55.7 In cohortele de pacienti cu DZ >50% au prezentat episoade de hipoglicemie asimptomatica (nerecunoscuta) ce au putut fi identificate numai prin CGMS1,2,3 46.6 Pacienti, % 50 25 n=70 n=40 n=30 Toti pacientii cu DZ DZ tip 1 DZ tip 2 Pacienti cu ≥1 episod de hipoglicemie asimptomatica, % 1. Chico A, et al. Diabetes Care 2003;26(4):1153-1157. 2. Weber KK, et al. Exp Clin Endocrinol Diabetes 2007;115(8):491-494. 3. Zick R, et al. Diab Technol Ther 2007;9(6):483-492. 18 18 18

Factori de risc pentru hipoglicemie HIPOGLICEMIA IN DIABETUL ZAHARAT Factori de risc pentru hipoglicemie Tratament cu insulina sau sulfoniluree1 Rata de filtrare glomerulara < 60 ml/min/1,73m2 Varsta2,3 Durata diabetului2 Program neregulat de mese3 Exercitiu fizic3 HbA1c < 7%4 Perioade de post Episoade anterioare de hipoglicemie5,6,7 Hipoglicemie asimptomatica8 Alcool9 NOTE REFERENCES IN NOTES BECAUSE OF NUMBERS 1. Asian-Pacific Type 2 Diabetes Policy Group. 4th Edition. 2005;1–58. 2. Henderson JN et al. Diabet Med. 2003;20:1016–1021. 3. Matyka K et al. Diabetes Care. 1997;20(2):135–141 4. Miller CD et al. Arch Intern Med. 2001;161:1653–1659. 5. Wright et al. J Diabetes Complications. 2006;20:395–401. 6. Chico A et al. Diabetes Care. 2003;26(4):1153–1157. 7. Canadian Diabetes Association. Can J Diabetes. 2008;32(suppl 1):S62–S64. 8. California Healthcare Foundation. J Am Ger Soc. 2003;51(5, suppl):S265–S280 9. Amiel SA et al. Diabet Med. 2008;25(3):245–254 1. Asian-Pacific Type 2 Diabetes Policy Group. 4th Edition. 2005;1–58. 2. Henderson JN et al. Diabet Med. 2003;20:1016–1021. 3. Matyka K et al. Diabetes Care. 1997;20(2):135–141 4. Miller CD et al. Arch Intern Med. 2001;161:1653–1659. 5. Wright et al. J Diabetes Complications. 2006;20:395–401. 6. Chico A et al. Diabetes Care. 2003;26(4):1153–1157. 7. Canadian Diabetes Association. Can J Diabetes. 2008;32(suppl 1):S62–S64. 8. California Healthcare Foundation. J Am Ger Soc. 2003;51(5, suppl):S265–S280 9. Amiel SA et al. Diabet Med. 2008;25(3):245–254 19 19

HIPOGLICEMIA IN DIABETUL ZAHARAT Tratament • Scaderea glicemiei la 60 – 80mg/dl impune luarea unei decizii: ingestie de hidrati de carbon; amânarea efortului fizic; modificarea dozei de insulina. • Scaderea glicemiei sub 50mg/dl necesita tratament prompt.

HIPOGLICEMIA IN DIABETUL ZAHARAT Tratamentul la pacientul constient cu DZ tip 1 • Se administreaza oral glucide cu absorbtie rapida (20 g HC): glucoza zahar - lichide dulci - la copil se administreaza 0,3 g glucoza/kg corp 10 g glucoza p.o. - ↑glicemia cu ˜ 40mg/dl pentru 30’ 15 g glucoza p.o. - ↑glicemia cu ˜ 35 mg/dl in 20’ 20 g glucoza p.o. - ↑ glicemia cu ˜ 60mg/dl pentru 60’ glicemia începe sa scada dupa ˜ 60’ de la ingestia glucozei   • Se continua cu alimente ce contin glucide cu absorbtie lenta: pâine, biscuiti, cereale.

HIPOGLICEMIA IN DIABETUL ZAHARAT Tratamentul la pacientul somnolent / inconstient cu DZ tip 1 • Glucoza iv (33 -50%) (20 – 50 ml glucoza 50%) • Glucagon adult: 1 mg im/iv copil: 15 µg/kgc im/iv contraindicatii: - hipoglicemie prelungita, - afectiuni hepatice, - alcoolici, - malnutriti. avantaje: - produce hiperglicemie rapid (10 -15 ’) - nivelul glicemiei începe sa scada dupa ˜ 1,5 ore.

HIPOGLICEMIA IN DIABETUL ZAHARAT Tratamentul hipoglicemiilor severe în DZ tip 2 tratat cu sulfoniluree • Glucoza iv (33% sau 50%) - 20 – 50 ml glucoza 50% • PEV glucoza 10% (durata variabila) • Tratament adjuvant: – diazoxid 300 mg iv repetat la 4h daca este necesar sau 300 mg p.o. la 4 h; – octreoctid. • Glucagonul este contraindicat (poate stimula secretia de insulina la pacienti cu rezerva functionala ß celulara). • Coma necesita spitalizare mai multe zile.

HIPOGLICEMIA IN DIABETUL ZAHARAT Complicatii hipoglicemiilor severe si prelungite • AVC, IMA • Encefalopatie posthipoglicemica; decerebrare partiala/totala • Hemoragie retiniana masiva cu pierderea vederii • Edem cerebral • Mortalitate crescuta (mai mare în cazul vârstnicilor cu durata mare a DZ si complicatii macrovasculare si în cazul hipoglicemiilor severe induse de sulfonilureice)

HIPOGLICEMIA IN DIABETUL ZAHARAT Educatia persoanelor din anturajul pacientului cu diabet zaharat • Cunoasterea simptomatologiei • Sa încerce sa administreze bolnavului un lichid dulce (apa cu zahar, suc de fructe, compot îndulcit) • Sa administreze i.m. sau s.c. o fiola de glucagon la pacientii cu DZ tip 1 • Sa aiba întotdeauna zahar/glucoza (la îndemâna) • Determinarea glicemiei în cazul suspectarii unei hipoglicemii • Cunoasterea perioadelor cu risc hipoglicemic

CUPRINS Definitie Clasificare Mecanisme compensatorii Efecte fiziopatologice Cauze Hipoglicemie la pacientul cu diabet zaharat Prevalenta Factori de risc Tratament Complicatii hipoglicemiilor severe si prelungite Educatia anturajului